INDIANAPOLIS — A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
“This powerful panel of just 11 genes successfully identified who has problems with alcohol abuse and who does not in tests in three patient populations on two continents, in two ethnicities and in both genders,” said Alexander B. Niculescu III, M.D., Ph.D., principal investigator and associate professor of psychiatry and medical neuroscience at the Indiana University School of Medicine.
The panel of genes is highly accurate in its differentiation of alcoholics from controls at a population level, and less so at an individual level, likely due to the major and variable role environment plays in the development of the disease in each individual, the authors noted. Nevertheless, such a test could identify people who are at higher or lower risk for the disease.
“As alcoholism is a disease that does not exist if the exogenous agent (alcohol) is not consumed, the use of genetic information to inform lifestyle choices could be quite powerful,” the authors wrote in the paper, published online Tuesday in the journal Translational Psychiatry.
“We believe this is the strongest result to date in the field of alcoholism and offers a comprehensive — though not exhaustive — window to the genetics and biology of alcoholism,” Dr. Niculescu said.
Dr. Niculescu, attending psychiatrist and research and development investigator at the Richard L. Roudebush Veterans Affairs Medical Center in Indianapolis, cautioned that genetic tests indicate risk, not certainty, and that “genes act in the context of environment.”
Alcohol is legal, widely available, and subject to advertising and social pressures, he noted; but knowing one has a genetic predisposition to alcohol abuse could encourage behavioral and lifestyle changes.
The researchers incorporated data from a German genome-wide study of alcoholism with data from a variety of other types of research into genetic links to alcoholism using a system called Convergent Functional Genomics. The work produced a group of 135 candidate genes.
The researchers then looked at the overlap between those 135 genes and genes whose expression activity was changed in a mouse model of stress-reactive alcoholism — research mice that respond to stress by consuming alcohol. The mouse model enables researchers to zero in on key genes that drive behavior without the myriad environmental effects that are present in humans.
The mouse model analysis narrowed the candidates down to the panel of 11 genes and 66 variations of those genes called single-nucleotide polymorphisms.
The researchers then determined that the panel of 11 genes could be used to differentiate between alcoholics and non-alcoholics (controls) in three different research populations for which genetic data and information about alcohol consumption were available: a group of Caucasian subjects and a group of African American subjects from the U.S., and a third group from Germany.
Many of the 11 genes also have been implicated as associated with other neuropsychiatric disorders including cocaine addiction, Parkinson’s disease, bipolar disorder, schizophrenia and anxiety — not too surprising given that basic brain biology is involved, and links between such diseases as alcoholism and bipolar disorder have been known clinically for many years, Dr. Niculescu said.
Some of the genes also suggest possible future routes for treatment and prevention, including genes that play a role in the activities of omega-3 fatty acids, for which there is some evidence of control of alcohol consumption in laboratory tests previously conducted by Dr. Niculescu and collaborators.
Other researchers involved in this work were Daniel Levey, Helen Le-Niculescu, Mikias Ayalew, Nikita Jain, Brigid Kirlin, Rebecca Learman, Evan Winiger, Zachary Rodd and Anantha Shekhar of the Indiana University School of Medicine; Nicholas Schork of The Scripps Research Institute; Josef Frank and Marcella Rietschel of the Central Institute of Mental Health, Mannheim, Germany; Falk Kiefer of Heidelberg University; Norbert Wodarz of the University of Regensburg; Bertram Müller-Myhsok of the Max Planck Institute of Psychiatry; Norbert Dahmen of the University of Mainz; Markus Nöthen of the University of Bonn; Richard Sherva and Lindsay Farrer of Boston University School of Medicine; Andrew Smith and Joel Gelernter of Yale University School of Medicine and Henry Kranzler of the University of Pennsylvania Perelman School of Medicine.
More information about this research can be found at www.neurophenomics.info.
The research was supported by an NIH Directors’ New Innovator Award (1DP2OD007363) and a VA Merit Award (1I01CX000139-01), as well as by NIH grants R01 DA12690, R01 DA12849, R01 AA11330 and R01 AA017535, and by grant FKZ 01GS08152 from the National Genome Research Network of the German Federal Ministry of Education and Research.